Hygiene group says coronavirus vaccine will not impact trading

Byotrol, the Daresbury-based hygiene group, said the likelihood of a coronavirus vaccine will not impact on its trading prospects.

Ahead of its annual general meeting today, the AIM-listed specialist infection prevention and control company, said this view is supported by industry trends clearly in evidence before – and now magnified by – COVID-19, all of which continue to favour Byotrol’s long-term positioning.

It said these focused on businesses and consumers taking increasingly proactive responsibility for protecting individuals against infection risk from viruses and bacteria, so increasing global demand, and competitors with weaker performance chemistries continuing to withdraw from its market in the UK and Europe as new regulations take hold, so reducing the supply of competing products and so multiplying opportunities for Byotrol’s future growth.

Directors said trading remains at healthy levels, across all business units and product sales.

Demand for IP licensing remains robust, with the team exploring multiple new opportunities, both in the UK and internationally.

The group said its net cash position remains strong, enabling it to maintain stock levels to fulfil customer demand, or, where appropriate, re-invest for the growth of the business.

Today’s statement said: “We expect results for the year to 31 March 2021 to meet current market expectations, notwithstanding the recent news on the development of potential vaccines against COVID-19.

“The directors remain highly confident in Byotrol’s longer term outlook.”